Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register

Abstract

ObjectiveTo evaluate the effect of different concomitant disease modifying antirheumatic drugs (DMARDs) on the persistence with antitumour necrosis factor (anti-TNF) therapies in patients with rheumatoid arthritis (RA).MethodThis analysis included 10 396 patients with RA registered with the British Society for Rheumatology Biologics Register, a prospective observational cohort study, who were starting their first anti-TNF therapy and were receiving one of the following DMARD treatments at baseline: no DMARD (n=3339), methotrexate (MTX) (n=4418), leflunomide (LEF) (n=610), sulfasalazine (SSZ) (n=308), MTX+SSZ (n=902), MTX+ hydroxychloroquine (HCQ) (n=401) or MTX+SSZ+HCQ (n=418). Kaplan–Meier survival analysis was used to study the persistence with anti-TNF therapy in each DMARD subgroup up to 5 years. Multivariate Cox proportional hazard models, stratified by anti-TNF used and start year and adjusted for a number of potential confounders, were used to compare treatment persistence overall and according to the reason for discontinuation between each of the DMARD subgroups, using MTX as reference.ResultsOne-year drug survival (95% CI) for the first anti-TNF therapy was 71% (71% to 72%) but this dropped to 42% (41% to 43%) at 5 years. Compared with MTX, patients receiving no DMARD, LEF or SSZ were more likely to discontinue their first anti-TNF therapy while patients receiving MTX in combination with other DMARDs showed better treatment persistence.ConclusionsThese results support the continued use of background DMARD combinations which include MTX. Consideration should be given to the discontinuation of LEF and SSZ monotherapy at the time anti-TNF therapies are started, with the possible exception of the SSZ+ETN combination.

Targeting Interleukin-6 in Rheumatoid Arthritis

“…The recommended dose as monotherapy is 8mg/kg given every 4 weeks. Various national registries have revealed that about one third of the patients worldwide are on biologic monotherapy [80,81]. Perhaps this is the strongest selling point of tocilizumab as to date, it is one of the few biologics given as a monotherapy that have shown superiority against methotrexate in head-to-head studies [44].…”

Turkish Compliance and Adaptation of EULAR 2013 Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biological Disease-Modifying Antirheumatic Drugs: Expert Opinion of TLAR

“…[46][47][48][49][50][51][52][53] TCZ has been found to be superior as monotherapy. 54,55 Achieved a Stable Low Disease Activity-State (DOSERA), also showed that dose reduction in TNF inhibitors is possible in RA.…”

New Recommendations for the Management of Rheumatoid Arthritis (Eular, 2013): The Role of Methotrexate

“…МТ повышает эффективность ингибиторов ФНОα (ИНФ и АДА) за счет разных механизмов, в том числе в связи с подавлением иммуногенности этих моноклональных ан-тител [46,102]. Наряду с материалами РПКИ, данные от-крытых наблюдательных исследований [103,104] и нацио-нальных регистров [105][106][107][108][109][110][111], а также их метаанализ [112] свидетельствуют о более высокой эффективности комби-нированной терапии МТ и ингибиторами ФНОα по срав-нению с монотерапией этими препаратами.…”